This was the stock's second consecutive day of gains.

A new injection to prevent HIV is expected to be approved by the U.S. Food and Drug Administration later this month.

While the broader market has struggled with the S&P 500 down 2.4% since December 2024, Gilead Sciences has surged ahead as ...

Later this month, the Food and Drug Administration is widely expected to approve a groundbreaking twice-yearly injection to ...

With a market cap of around $136 billion, Gilead Sciences, Inc. (GILD) is a biopharmaceutical company. The Foster City, ...

A Gilead Sciences-backed therapy made with a patient's own white blood cells shrank tumors in 62% of patients with recurrent ...

Gilead's HIV drug lenacapavir earns FDA priority review after strong trial results, with the company planning to double U.S.

Jefferies analyst Michael Yee reaffirmed a Buy rating on Gilead Sciences Inc. (NASDAQ:GILD), maintaining his price target at ...

At Gilead, we’re advancing new ways to help end the HIV epidemic by delivering innovative therapies to those who need them ...

Shares of Gilead Sciences Inc. GILD slid 1.06% to $108.91 Monday, on what proved to be an all-around favorable trading ...

Gilead Sciences is well-positioned to continue to strengthen its position as a leader in the HIV therapy market. Learn more ...

Gilead Sciences' TROP2-targeting drug Trodelvy is already used as a third-line treatment for PD-L1-positive triple-negative ...